Previously, the companies had engaged in a research collaboration to develop an assay to evaluate the potential to predict benefit from KEYTRUDA. The expanded collaboration is for the development and commercialization of the selected gene expression signature on NanoString's nCounter® Dx Analysis System as a diagnostic assay to predict response to KEYTRUDA in multiple tumor types.
"We look forward to working with
"We are excited to expand our collaboration with Merck to develop this novel assay for predicting response to
anti-PD-1 therapies such as KEYTRUDA. We believe this gene signature has the potential to become the basis for a universally available assay that serves as the 'gold standard‘ for informing treatment with immuno-oncology therapies," said
Under the terms of the expanded collaboration agreement,
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the likelihood of this collaboration to translate genomic discoveries to clinical assays, NanoString's plans to develop, receive regulatory approvals for, and commercialize clinical assays and companion diagnostics on the nCounter platform that will predict response to KEYTRUDA and other anti-PD-1 therapies, and about future payments that may or may not be received by
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are either registered trademarks or trademarks of NanoString Technologies, Inc.
Leigh Salvoof Westwicke PartnersFor NanoString Technologiesleigh.email@example.com 415-513-1281
News Provided by Acquire Media